Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis

Abstract Background and Aim Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. Methods Entecavir (ETV) and TAF were given to 66...

Full description

Bibliographic Details
Main Authors: Kento Inada, Shun Kaneko, Masayuki Kurosaki, Koji Yamashita, Sakura Kirino, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Jun Itakura, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Ryuichi Okamoto, Namiki Izumi
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:JGH Open
Subjects:
de novo hepatitis
hepatitis B virus reactivation
tenofovir alafenamide
Online Access:https://doi.org/10.1002/jgh3.12636

Internet

https://doi.org/10.1002/jgh3.12636

Similar Items